Many attempts at measuring blood glucose have failed for a variety of reasons.
We have a straight forward means of measuring glucose and other analyses in the blood on a real time basis. This will enable future automated measurements and treatments for the ICU.
I is estimated that the US market is 500M. based on disposable cost.
We have completed in-vivo animal studies to prove the technologies. It is an LLC that has been self-funded. 600K.